KR101891465B1 - Transdermal drug delivery patch, transdermal drug delivery system and monitoring method of drug dosage - Google Patents

Abstract

The present invention relates to a transdermal drug delivery patch, a transdermal drug delivery system, and a drug dosage monitoring method. According to the present invention, the transdermal drug delivery patch includes: a first chamber having a drug injection button arranged on an upper end unit and stores drugs; a second chamber which has an open surface coming in contact with the skin, has a micro-needle array arranged on the inner part of another surface facing the open surface while having micro-needles arranged toward the skin, includes a micro-needle button for making the micro-needle array come in contact with the skin, and provides the drugs to the skin; and a fluid channel which connects the first and second chambers while providing the drugs to the second chamber from the first chamber. When the micro-needle button of the second chamber is pressed, the micro-needle array comes in contact with the skin. Micro-needle holes are formed on the skin by using the micro-needle array. When the drugs are provided to the second chamber, the drugs can be delivered to the inside of the body through the micro-needle holes.

Description

TECHNICAL FIELD [0001] The present invention relates to a transdermal drug delivery patch, a transdermal drug delivery system, and a method for monitoring a drug dose. [0002] The present invention relates to a transdermal drug delivery patch,

The present invention relates to a percutaneous drug delivery patch, and more particularly to a percutaneous drug delivery patch capable of easily and efficiently delivering a drug to a body, a percutaneous drug delivery system capable of monitoring a drug dose, To a method for monitoring drug dosage.

The transdermal drug delivery patch is a patch that can deliver medication through the skin. Because it delivers the drug by minimally invading or non-invading the skin, it is less painful than the drug administration method such as injection, Compared with the administration method, it has an advantage that it does not burden the digestive tract or the liver.

However, the transdermal drug delivery patch generally delivers the drug contained in the patch through the diffusion to the body. The diffusion rate is decreased due to the stratum corneum present in the outermost part of the skin, and the permeability of the drug is relatively low. In addition, since various skin layers are delivered through diffusion, it is difficult to instantly administer the drug according to the patient's needs, and it is difficult to quantitatively calculate or predict the amount of the drug penetrating into the body.

Recently, in order to solve such a problem, research and development of a system that emits drugs according to various stimuli such as light, temperature, ultrasound, magnetic field, and mechanical stimulation in an on-demand manner according to a patient's demand However, in order to supply such stimulation, additional expensive equipments are required and it is not possible to deliver them promptly and easily.

Therefore, there is a further demand for development of a transdermal drug delivery system that can economically and easily adjust the dose of the drug as needed, and further, quantitatively monitor the amount of drug substantially penetrated into the body .

It is an object of the present invention to provide a transdermal drug delivery patch which can easily and efficiently deliver drugs into the body.

It is another object of the present invention to provide a transdermal drug delivery system capable of quantitatively monitoring the amount of drug infiltrated into the body.

It is yet another object of the present invention to provide a method for monitoring drug dosage.

A transdermal drug delivery patch for one purpose of the present invention comprises a first chamber containing a drug injection button disposed at an upper end and storing a drug; A microneedle array having microneedles arrayed on one side facing the skin and facing the skin on the other side facing the skin, and a microneedle button for contacting the microneedle array with the skin, A second chamber for providing the drug to the patient; And a fluid channel connecting the first chamber and the second chamber to provide a drug from the first chamber to the second chamber, wherein when pressing the microneedle button of the second chamber, When the microneedle array is in contact with the skin, the microneedle holes are formed in the skin by the microneedle array, and the drug is provided in the second chamber, the drug can be delivered into the body through the microneedle holes have.

In one embodiment, the second chamber may further include a cover film that covers an opened one surface in contact with the skin, and when the microneedle button is pressed, the microneedle array can penetrate.

At this time, the cover film may be a film having at least one of a material and a thickness that allows penetration of the microneedle array.

At this time, the cover film may be a film having a plurality of openings so that the array of microneedles can be penetrated.

In one embodiment, the first chamber may be completely filled with the drug.

At this time, the first chamber may be a deformable body deformable by an external force.

At this time, the rigid film having rigidity may be disposed on the skin contact surface of the first chamber in contact with the skin, or the skin contact surface may be formed of a rigid material.

At this time, when the drug injection button is pushed, the drug stored in the first chamber is supplied to the second chamber through the fluid channel, and the first chamber is reduced in volume by the volume of the drug supplied to the second chamber can do.

In this case, the first chamber is formed of a polymer having elasticity, and the drug injection button includes a micro-penetration portion passing through the drug injection button toward the first chamber, and the micro- , And can be closed when no external force acts on the drug injection button.

In one embodiment, the transdermal drug delivery patch may comprise a pressure measurement sensor capable of measuring the pressure of the drug injection button.

In one embodiment, the fluid channel may be a microfluidic channel having a micro-sized diameter and capable of fluid movement.

Another object of the present invention is to provide a percutaneous drug delivery system including a first chamber for storing a drug, A microneedle array having microneedles arrayed on one side facing the skin and facing the skin on the other side facing the skin, and a microneedle button for contacting the microneedle array with the skin, A second chamber for providing the drug to the patient; And a fluid channel connecting the first chamber and the second chamber to provide a drug from the first chamber to the second chamber, wherein when pressing the microneedle button of the second chamber, The microneedle array is contacted with the skin, the microneedle holes are formed in the skin by the microneedle arrays, and when the drug is provided in the second chamber, the drug is delivered into the body through the microneedle holes And a pressure measurement sensor capable of measuring the pressure of the drug injection button, wherein when pressure is applied to the drug injection button, the pressure of the drug injection button is measured, A data obtaining unit obtaining the pressure change rate data of the drug injection button; A data transmission unit connected to be able to communicate with the data acquisition unit and transmitting pressure change rate data of the drug injection button acquired by the data acquisition unit through wire or wireless communication; A data receiving unit connected to be able to communicate with the data transmitting unit and receiving pressure change rate data of the drug injection button transmitted through wired or wireless communication; And a stored database that quantifies the amount of drug supplied from the first chamber to the second chamber in accordance with the rate of change of the pressure of the drug injection button, wherein the pressure change rate data of the received drug injection button is compared with the database, And judging an amount of the drug provided from the chamber.

In one embodiment, the second chamber further comprises a database quantifying the amount of drug infiltration into the skin according to the amount of the drug provided, wherein the determination unit determines the pressure change rate data of the received drug injection button, A stored database quantifying the amount of drug provided from the first chamber to the second chamber according to the rate of change of pressure and a second database comparing the amount of drug supplied to the skin with the amount of drug given to the second chamber, The dosage of the drug can be determined.

A method for monitoring a drug dose for another purpose of the present invention includes a first chamber for storing a drug, the drug chamber comprising a drug injection button disposed at an upper end thereof; A microneedle array having microneedles arrayed on one side facing the skin and facing the skin on the other side facing the skin, and a microneedle button for contacting the microneedle array with the skin, A second chamber for providing the drug to the patient; A fluid channel connecting the first chamber and the second chamber to provide a drug from the first chamber to the second chamber; And a pressure measurement sensor capable of measuring a pressure of a drug injection button of the first chamber, wherein the microneedle button of the percutaneous drug delivery patch is pressed to bring the microneedle array into contact with the skin, Forming microneedle holes in the skin; Providing a drug from the first chamber to the second chamber by pressing the drug injection button to deliver the drug to the skin where the micro needle holes are formed; Measuring pressure of the pressurized drug injection button to obtain pressure change rate data of the drug injection button; Transmitting the acquired pressure change rate data through wired or wireless communication; Receiving the transmitted pressure change rate data through wired or wireless communication; And comparing the received rate of pressure change data with a database quantifying the amount of drug provided from the first chamber to the second chamber according to the rate of change of the drug injection button to determine the amount of drug provided to the skin do.

In one embodiment, after determining the amount of drug provided from the first chamber, the amount of drug provided from the first chamber may be quantified by quantifying the amount of drug penetration into the skin according to the amount of drug provided by the second chamber And comparing the amount of the drug to the skin with respect to a database.

According to the percutaneous drug delivery patch, the percutaneous drug delivery system, and the method of monitoring the drug dose of the present invention, the percutaneous drug delivery patch of the present invention forms micro needle holes in the skin through a micro needle array, The drug can be injected into the body through the microneedle holes formed in the skin, so that the drug can be quickly delivered into the body at a high absorption amount. In addition, the transdermal drug delivery patch of the present invention prevents the negative pressure from being formed in the first chamber storing the drug, thereby preventing the backflow of the drug from the second chamber that delivers the drug to the skin. Therefore, the drug can be delivered to the skin in the desired amount. In addition, the transdermal drug delivery system of the present invention includes a database that empirically quantifies and correlates the correlation between the amount of released drug and the amount of drug permeated into the body depending on the force of pressing the drug injection button And the sensor for measuring the pressure of the drug injection button of the percutaneous drug delivery patch of the present invention can be quantitatively obtained by the amount of the drug released according to the pressure for pressing the drug injection button, Can be monitored and controlled. At this time, the sensor of the percutaneous drug delivery patch of the present invention may be connected to an additional display device by wire or wireless communication to quantitatively display the amount of drug released from the first chamber and the amount of drug administered to the skin. In addition, the transdermal drug delivery system of the present invention can be combined with a device capable of remotely controlling the amount of drug released and the time of release, thereby providing a remote on- demand drug delivery system.

FIG. 1A is a view for explaining a percutaneous drug delivery patch according to an embodiment of the present invention. FIG.
1B is a view for explaining a percutaneous drug delivery patch according to another embodiment of the present invention.
1C is a view for explaining a percutaneous drug delivery patch according to another embodiment of the present invention.
FIG. 1D is a view illustrating a drug delivery patch according to another embodiment of the present invention. FIG.
2 is a view for explaining drug delivery using the transdermal drug delivery patch of the present invention.
3 is a view for explaining a percutaneous drug delivery patch according to an embodiment of the present invention.
4 is a view for explaining a percutaneous drug delivery patch according to an embodiment of the present invention.
FIG. 5 illustrates a percutaneous drug delivery patch according to an embodiment of the present invention. Referring to FIG.
FIG. 6 is a view for explaining the drug release amount of the percutaneous drug delivery patch according to an embodiment of the present invention.

Hereinafter, embodiments of the present invention will be described in detail with reference to the accompanying drawings. The present invention is capable of various modifications and various forms, and specific embodiments are illustrated in the drawings and described in detail in the text. It is to be understood, however, that the invention is not intended to be limited to the particular forms disclosed, but on the contrary, is intended to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the invention. Like reference numerals are used for like elements in describing each drawing.

The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. The singular expressions include plural expressions unless the context clearly dictates otherwise. In the present application, the term "comprises" or "having ", etc. is intended to specify that there is a feature, step, operation, element, part or combination thereof described in the specification, , &Quot; an ", " an ", " an "

Unless defined otherwise, all terms used herein, including technical or scientific terms, have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Terms such as those defined in commonly used dictionaries are to be interpreted as having a meaning consistent with the contextual meaning of the related art and are to be interpreted as either ideal or overly formal in the sense of the present application Do not.

1A to 1D are views for explaining the transdermal drug delivery patch of the present invention.

FIG. 1A is a view showing a percutaneous drug delivery patch according to an embodiment of the present invention, and FIG. 1B is a view illustrating a percutaneous drug delivery patch according to another embodiment of the present invention. FIG. 1C is a view showing a transdermal drug delivery patch according to another embodiment of the present invention, and FIG. 1D is a view showing a transdermal drug delivery patch according to another embodiment of the present invention.

1A to 1D, the percutaneous drug delivery patches 101, 102, 103 and 104 of the present invention include a first chamber 110 for storing a drug, a second chamber 120 for delivering the drug to the skin And a fluid channel 130 connecting between the first chamber 110 and the second chamber 120.

The first chamber 110 is connected to the first chamber 110 and the second chamber 110 is connected to the fluid channel 130. The first chamber 110 is a chamber for storing medicines, It is a closed chamber with its face closed. At this time, the first chamber 110 may be completely filled with the drug. The medicament may be completely filled into the first chamber 110 to the connection between the first chamber 110 and the fluid channel 130 and the first chamber 110 and the fluid channel 130 Or may be filled up to a point below the connection part or the connection part between the fluid channel 130 and the second chamber 120.

The first chamber 110 includes a drug injection button 112 disposed at an upper end thereof. The drug injection button 110 may be formed of a flexible material having elasticity. In other words, the drug injection button 110 can be deformed in shape when pressed, and can be returned to its original shape when the pressure applied to the drug injection button 110 is removed. The percutaneous drug delivery patches 101, 102, 103 and 104 of the present invention are configured such that the drug stored in the first chamber 110 is discharged from the first chamber 110 to the fluid channel The drug is not released from the first chamber 110 when the drug injection button 112 is not pressed.

At this time, the first chamber 110 may be a deformable body that can be deformed by an external force. For example, the first chamber 110 may be formed of a material having flexibility so that the physical shape of the first chamber 110 can be deformed when an external force is applied thereto. At this time, the first chamber 110 is formed of a material having a rigid skin contact surface that contacts the skin, or a hard film (not shown) having rigidity is disposed on the skin contact surface. The first chamber 110 The skin contact surface contacting the skin of the user can have rigidity. The first chamber 110 has a rigidity on the surface of the first chamber 110 that is in contact with the skin, thereby pressing the drug injection button 112 to discharge the drug. The elasticity of the skin upon deformation or pressure of the skin on the skin- It is possible to prevent the chamber 110 from being deformed to change the amount of drug discharge. That is, by minimizing the deformation of the skin or the deformation of the first chamber 110 at the skin contact surface as the drug injection button 112 is depressed, the amount of the drug supplied from the first chamber 110 to the second chamber 120 So that the amount of the drug supplied from the first chamber 110 to the second chamber 120 can be made constant. Therefore, the amount of desired drug can be finely controlled, and more precisely, can be provided from the first chamber 110 to the second chamber 120.

The hard film is a hard film, which is capable of preventing deformation of the first chamber 110 induced from the elasticity of the skin upon drug injection or preventing deformation of the skin. In one example, the hard film may be a thin film such as a cellophane tape. However, the present invention is not limited thereto. In the present invention, the hard film can prevent the deformation of the first chamber 110, which is induced from elasticity of the skin, . In the case where the first chamber 110 has rigidity at the lower end via the hard film, the hard film may include the transcutaneous drug delivery patches 101, 102, 103, and 103 of the present invention in which the first chamber 110 is located, 102, 103 and 104 of the present invention in which the second chamber 120 is located, as shown in FIG. At this time, the hard film may be a film through which a microneedle array of the second chamber 120 can pass, such as a cover film 126 covering one open side of the second chamber 120. The second chamber 120 will be described in more detail with reference to the second chamber 120.

Further, the first chamber 110 may be formed of a material having elasticity, and may be returned to its original shape when a deformed body deformed by an external force or an external force is removed. The drug injection button 112 of the first chamber 110 is provided with a micro-penetration portion (not shown) passing through the drug injection button 112 toward the first chamber 110 so that negative pressure is not formed in the first chamber 110 114). 1A and 1B illustrate the shape of the micro-penetration portion 114, the micro-penetration portion 114 of the present invention is substantially opened when an external force acts on the drug injection button 112, And may be in a closed state when an external force does not act on the button 112. [ For example, in order to form the pressure injection button 112 of the present invention, by pushing the pressure injection button 112 with a substance having an attachment, such as a fine needle, while the pressure injection button 112 is being pressed, (114) can be formed in the through hole (112). In the present invention, closing of the micro-penetration portion 114 of the drug injection button 112 means that external air does not flow or internal air does not flow out, and the opening of the micro- Is discharged. The micro piercing portion 114 formed in the drug injection button 112 is normally closed when no external force is applied to the drug injection button 112. However, when the drug injection button 112 is pressed, The drug infusion button 112 can be deformed by the pressure exerted on the second chamber so that the micro piercing portion 114 is opened to allow the outside air to flow into the inside to fill the volume of the drug supplied to the second chamber, The atmospheric pressure and the inner pressure of the first chamber 110 are balanced so that the negative pressure generated in the first chamber 110 can be prevented when the pressure applied to the drug injection button 112 is removed. That is, it is possible to prevent the drug discharged from the first chamber 110 to the second chamber 120 from flowing back to the first chamber 110 again. The transdermal drug delivery patches 101, 102, 103 and 104 of the present invention are capable of quantifying the amount of drug released from the first chamber 110 and provided to the second chamber 120 by preventing backflow of the drug have.

Alternatively, the volume of the chamber may be reduced by the volume of the drug supplied to the first chamber 110 from the first chamber 110 to the second chamber 120. A more detailed description thereof will be described with reference to Figs. 1C and 1D. The first chamber 110 may be formed of a contractible material to reduce the volume of the first chamber 110 itself by the volume of the drug provided to the second chamber 120, . Alternatively, the first chamber 110 may be configured such that the drug injection button 112 disposed at the upper end of the first chamber 110 has a volume of drug released from the first chamber 110, So that the volume of the first chamber 110 may be reduced. At this time, the first chamber 110 may be completely filled with the drug even though the drug is released, because the volume of the first chamber 110 decreases as the drug is released. Further, by measuring the volume of the reduced first chamber 110, it is possible to quantify the amount of drug released from the first chamber 110 and provided to the second chamber 120.

The fluid channel 130 is a channel connecting the first chamber 110 and the second chamber 120 and is a channel that can supply the drug from the first chamber 110 to the second chamber 120. In one example, the fluid channel 130 may be a microfluidic channel having a micro-sized diameter and capable of fluid movement. 1A to 1D illustrate the first chamber 110 and the fluid channel 130 connected to the lower end of the first chamber 110. The fluid channel 130 and the first chamber 110 The position of the connected connection portion is not particularly limited as long as all the drugs stored in the first chamber 110 can be transmitted to the second chamber 120.

The second chamber 120 is a chamber for contacting the skin to be supplied with the drug and delivering the drug to the skin through the medicine delivered from the first chamber 110, Is an open, open chamber. The second chamber 120 includes an open side in contact with the skin, a microneedle array 122 in which microneedles are disposed toward the skin in the other side in contact with the skin, and a second chamber 120, And a micro needle button 124 disposed at the upper end and contacting the micro needle array 122 with the skin.

The microneedles may be in the form of micro-sized fine needles, for example, in the form of a patch with one or more microneedles disposed on one side of the microneedle array 122. When the micro needle button 124 is pressed, the microneedle array 126 connected to the microneedle button 124 is lowered toward the skin to make contact with the skin, and the microneedle array 126 disposed on the skin with the microneedle array 126 A micro needle hole having the same shape is formed. When the pressure applied to the microneedle button 124 is removed, the microneedle array 126 is raised and positioned again on the inner surface of the second chamber 120. At this time, when the drug is supplied to the second chamber 120, the drug is delivered into the body through the microneedle holes formed by the microneedle array 122 on the skin. The drug delivery method using the transdermal drug delivery patch of the present invention will be described in more detail with reference to FIG.

In addition, the second chamber 120 may include, for example, a cover film 126 covering the opening on one side of the opening, which is in contact with the skin. At this time, the cover film 126 may be a film through which the microneedle array 122 can penetrate when the microneedle button is pressed. Specifically, the cover film 126 through which the microneedle array 122 can penetrate can be a film having at least one of the properties of a material and a thickness that the microneedle array 126 can penetrate, or a plurality of openings are formed The microneedle array 126 may be a film that can be penetrated. In one example, the film having a plurality of openings may be a mesh-like film.

In addition, the percutaneous drug delivery patches 101, 102, 103, and 104 of the present invention may include a pressure measurement sensor 116 capable of measuring the pressure of the drug injection button 112. The pressure measurement sensor 116 can measure the pressure change rate of the drug injection button by measuring the pressure change acting on the drug injection button. For example, the pressure measurement sensor 116 may be a strain measurement sensor that measures the degree of morphological deformation according to the pressure applied to the drug injection button 112. In the percutaneous drug delivery patches 101, 102, 103 and 104 of the present invention, the pressure measurement sensor 116 senses a pressure change of the drug injection button 112 and, as long as the pressure change degree can be measured, But it may be located between the drug injection button 112 and the first chamber 110. The drug injection button 112 may be located in the transdermal drug delivery patch 101, 102, 103, 104 of the invention. At this time, the length of the pressure measurement sensor 116 may be longer than the maximum diameter or width of the drug injection button 112. The pressure measurement sensor 116 has a longer length than the drug injection button 112 so that the pressure measurement sensor 116 can measure the pressure change of the drug injection button 112 without breaking even when the pressure injection button 112 is pressed Can be detected. In one example, the drug injection button 112 may be in the form of a cylinder, wherein the length of the pressure measurement sensor 116 may be longer than the maximum diameter of the drug injection button 112.

2 is a view for explaining drug delivery using the transdermal drug delivery patch of the present invention.

Referring to FIG. 2 together with FIGS. 1A to 1D, in order to deliver a drug to the skin using the transdermal drug delivery patches 101, 102, 103 and 104 of the present invention, first, the transdermal drug delivery The patches 101, 102, 103 and 104 are placed on the target skin and the micro needle button 124 of the percutaneous drug delivery patches 101, 102, 103 and 104 of the present invention is pressed, Holes.

At this time, as described above, the microneedle array 122 connected to the microneedle button 124 is lowered by the pushing of the microneedle button 124 to come into contact with the target skin, When the losing pressure is removed, it rises again and is located at the original position. Accordingly, micro needle holes formed by the micro needles of the micro needle array 122 are present on the target skin.

The drug injection button 112 of the first chamber 110 is then pressed to provide the drug from the first chamber 110 through the fluid channel 130 to the second chamber 120.

The drug delivered from the first chamber 110 to the second chamber 120 is supplied to the target skin surface through the second chamber 120 opened to the target skin, Through the skin. Unlike the transdermal drug delivery system, which generally delivers the drug into the body by diffusion at the surface of the skin, the transdermal drug delivery patches 101, 102, 103 and 104 of the present invention can deliver drugs directly into the body The drug can be rapidly delivered into the body at a high penetration rate. In addition, since the micro needle holes are formed on the surface of the skin using micro needles, there is an advantage that the pain is almost undetectable as compared with the injection type drug injection method.

At this time, the amount of the drug discharged from the first chamber 110 can be adjusted according to the force for pressing the drug injection button 112 of the first chamber 110, and the amount of drug discharged from the drug injection button 112 of the first chamber 110 112 can be monitored and adjusted from the transdermal drug delivery patch of the present invention to the skin by experimentally quantifying and quantitating the dose of the released drug to the skin . A more detailed description thereof will be described later with reference to the percutaneous drug delivery system of the present invention.

Referring to FIGS. 1A to 1D and 2, the transdermal drug delivery system of the present invention will be described in detail. The transdermal drug delivery system of the present invention comprises the transdermal drug delivery patches 101, 102, 103, 104) for acquiring the pressure change rate data of the drug injection button 112 of the percutaneous drug delivery patches 101, 102, 103, 104 of the present invention, a drug injection button 112 , A data receiving section for receiving the pressure change rate data of the drug injection button 112, and a control section for determining the amount of the drug provided from the first chamber from the pressure change rate data of the drug injection button 112 And a judgment unit.

Specifically, the data acquiring unit is a portion having a pressure measurement sensor 126 capable of measuring the pressure of the drug injection button 112 of the percutaneous drug delivery patches 101, 102, 103, 104 of the present invention, When the drug injection button 112 is pressed, the pressure change of the drug injection button 112 is sensed through the pressure measurement sensor 126, and the degree of pressure change, that is, the rate of pressure change is measured, 112 can be obtained.

The data transmitting unit is connected to communicate with the data obtaining unit and transmits the pressure change rate data of the drug injection button 112 acquired by the data obtaining unit through wired or wireless communication.

The data receiving unit is connected to be capable of communicating with the data transmitting unit, and receives the pressure change rate data of the drug injection button 112 transmitted from the data transmitting unit via wired or wireless communication.

The determination unit is connected to the data receiving unit so as to be communicable with the drug injection button 112. The drug injection button 112 receives the data from the data receiving unit and stores a database for quantifying the dose of the drug to the skin according to the rate of change of the pressure of the drug injection button 112, Is compared with the stored database to determine the dosage of the drug provided to the skin.

The database for quantifying the amount of the drug provided to the skin according to the rate of change of the pressure of the drug injection button 112 is a database for calculating the amount of drug released due to the force pressing the drug injection button 112 of the first chamber 110, Of the present invention can be a database obtained by empirically quantifying the amount of the drug administered to the skin. Specifically, the database may be a database that quantifies the amount of drug supplied from the first chamber 110 to the second chamber 120 according to the rate of change of the drug injection button 112, A database for quantifying the amount of the drug supplied from the first chamber 110 to the second chamber 120 according to a rate of change of the pressure of the drug injection button 112 and a database for quantifying the amount of the drug supplied to the second chamber 120 And a database that quantifies the dose of the drug that penetrates into the skin. For example, the determination unit may calculate the rate of pressure change data of the received drug injection button 112 based on the amount of drug supplied from the first chamber 110 to the second chamber 120 according to the rate of change of the drug injection button 112 To determine the amount of drug provided from the first chamber 110 and to determine the amount of drug provided from the first chamber 110 based on the amount of drug provided by the second chamber 120 Compared to a database that quantifies the amount of drug penetration into the skin, the dosage of the drug to the skin can be determined.

For example, the transdermal drug delivery system of the present invention may include a display unit for displaying a drug infiltration amount determined by the determination unit. The display unit may be connected to the transcutaneous drug delivery system of the present invention so as to communicate with at least one of wired and wireless communication, and may communicate with the second chamber 120 from the first chamber 110 determined by the determination unit The amount of drug provided, and the amount of drug penetration into the skin can be received and displayed. For example, the display unit may be a device such as a cellular phone that receives the drug infiltration amount determined by the determination unit through wireless communication.

In addition, the transdermal drug delivery system of the present invention may include a control unit capable of controlling a drug injection amount. The control unit may be a part capable of controlling a drug release amount and a drug release time from the first chamber 110 of the percutaneous drug delivery system of the present invention and accordingly, The amount can be adjusted. At this time, the control unit may perform the control remotely. For example, the control unit may include a pressurizing device connected to the drug injection button 112 so as to be capable of precisely pressurizing the drug injection button 112, thereby pressing the drug injection button 112, The second chamber 120 may be modified to provide medicines stored in the first chamber 110 to the second chamber 120.

In order to monitor the dose of drug using the transdermal drug delivery system of the present invention, first, the percutaneous drug delivery patches (101, 102, 103, 104) of the present invention provided in the transdermal drug delivery system of the present invention To deliver the drug to the skin.

Since the drug delivery using the percutaneous drug delivery patches 101, 102, 103, and 104 of the present invention is substantially the same as that described with reference to FIG. 2, detailed description thereof will be omitted, do.

At this time, the rate of pressure change of the drug injection button 112 of the percutaneous drug delivery patches 101, 102, 103, 104 of the present invention is measured and the pressure change rate data of the drug injection button 112 is obtained. At this time, the acquisition of the pressure change rate data of the drug injection button 112 may be performed in the data acquisition unit of the percutaneous drug delivery system of the present invention.

Subsequently, the obtained pressure change rate data of the drug injection button 112 is transmitted, and the pressure change rate data of the transmitted drug injection button 112 is received.

Transmission and reception of the strain data of the drug injection button 112 can be performed through wired or wireless communication and transmission and reception of the pressure change rate data of the drug injection button 112 can be performed by the transdermal drug delivery system of the present invention A data transmission unit and a data reception unit.

Next, the received pressure change rate data is compared with a database that quantifies the drug delivery amount to the skin according to the rate of change of the pressure of the drug injection button 112, thereby determining the dosage of the drug provided to the skin.

At this time, the determination of the dosage of the drug provided to the skin may be performed by comparing the received pressure change rate data with the amount of the drug supplied from the first chamber 110 to the second chamber 120 according to the rate of change of the pressure of the drug injection button 112 By determining the amount of the drug provided from the first chamber 110, as compared with a database obtained by quantifying the amount of the drug.

Alternatively, after determining the amount of drug provided from the first chamber 110 to the second chamber 120, the amount of drug provided from the first chamber 110 may be determined based on the amount of drug provided to the second chamber 120 The amount of drug penetration into the skin according to the amount of the drug.

The determination of the dose of the drug provided to the skin can be performed in the judgment unit of the transdermal drug delivery system of the present invention and the database is substantially the same as that described in the transdermal drug delivery system of the present invention, A description thereof will be omitted.

According to the present invention, the percutaneous drug delivery patches 101, 102, 103 and 104 of the present invention form micro needle holes in the skin through the microneedle array 122, and drugs are provided in the second chamber 120 The drug can be penetrated into the body through the micro needle holes formed in the skin, and the drug can be rapidly delivered into the body at a high absorption amount.

Further, by reducing the volume or preventing the negative pressure from being formed in the first chamber 110 storing the drugs of the percutaneous drug delivery patches 101, 102, 103, 104 of the present invention, It is possible to prevent the backflow of the drug from the two chambers 120 to the first chamber 110. Therefore, the desired amount of drug can be delivered to the skin.

In addition, the percutaneous drug delivery system of the present invention including the percutaneous drug delivery patches 101, 102, 103, and 104 of the present invention is capable of controlling the amount of drug released due to the force pressing the drug injection button 112, The amount of the drug, the amount of the drug infiltrated into the body, and the correlation between them are empirically formulated and quantified in the form of a database, and the drug injection buttons 112 (102, 103, 104) of the percutaneous drug delivery patches The amount of the drug released according to the pressure for pressing the drug injection button 112 can be quantitatively obtained by providing the sensor 116 that can detect the change in pressure of the drug injection button 112 and measure the degree of the change. That is, the transdermal drug delivery system of the present invention is capable of easily quantifying and monitoring the amount of the drug penetrated into the body, controlling the dosage of the required drug according to the degree of pressing the drug injection button 112 .

In addition, the transdermal drug delivery system of the present invention can be used as a remote drug delivery system that can control the release of a drug according to the situation of a patient, by combining it with a device capable of remotely controlling the release amount and the release time have.

Hereinafter, the present invention will be described in more detail with reference to specific examples.

First, a transdermal drug delivery patch according to an embodiment of the present invention was prepared using PDMS, which is an elastic polymer.

3 is a view for explaining a percutaneous drug delivery patch according to an embodiment of the present invention.

FIG. 3 (a) is a photograph showing a transdermal drug delivery patch according to an embodiment of the present invention, and FIG. 3 (b) This is a photograph showing the array.

Referring to FIG. 3, the percutaneous drug delivery patch according to an embodiment of the present invention includes a pressure measurement sensor capable of measuring pressure of a drug injection button, a micro-penetration part formed in a drug injection button, And a micro needle array having a length of 900 mu m on one side and a maximum diameter of 300 mu m arranged in 4x4.

Next, a loading force applied to the drug injection button according to time was checked when the drug injection button of the percutaneous drug delivery patch according to an embodiment of the present invention was pressed. The results are shown in Fig.

FIG. 4 is a view for explaining a percutaneous drug delivery patch according to an embodiment of the present invention. FIG. 4 is a cross-sectional view illustrating a drug delivery patch according to the present invention in which a first chamber is filled with air, water, FIG. 3 is a graph showing time-dependent load power applied to each drug injection button after the drug injection button of the percutaneous drug delivery patch according to one embodiment of the present invention.

Referring to FIG. 4, the percutaneous drug delivery patches according to an embodiment of the present invention in which the first chamber is filled with air, water, and oil, respectively, immediately increase as soon as the drug injection button is pressed, The force was fixed at 0.6 mm corresponding to 3 N. It was then restored for about 4 seconds. Also, it can be seen that the percutaneous drug delivery patch according to an embodiment of the present invention can achieve almost the same result even when filled with various fluids in the first chamber.

That is, the amount injected from the first chamber through the fluid channel into the second chamber, regardless of the type, viscosity, or the like of the substance stored in the first chamber of the transcutaneous drug patch of the present invention, . This means that the transdermal drug delivery patch of the present invention can be used as a patch capable of delivering various drugs regardless of the type of drug.

Next, in order to confirm the drug delivery of the percutaneous drug delivery patch according to an embodiment of the present invention, the percutaneous drug delivery patch according to an embodiment of the present invention is applied to the skin of a rat, and the drug injection button is pressed . The results are shown in Fig.

FIG. 5 is a view for explaining a percutaneous drug delivery patch according to an embodiment of the present invention. FIG. 5 (a) is a cross-sectional view of a drug injection button of a percutaneous drug delivery patch according to an embodiment of the present invention, (B) is a graph showing the wetted area of the drug released during 4 pressurization; FIG. 4 (b) is a graph showing the wet fluorescence image of rat skin showing the wetted area of released drug by repeatedly pressing with force;

Referring to FIG. 5 (a), it is confirmed that the drug is supplied from the microfluidic channel to the second chamber by pressing the drug injection button of the percutaneous drug delivery patch according to an embodiment of the present invention.

Referring to FIG. 5 (b), as the number of pressing the drug injection button of the percutaneous drug delivery patch according to an embodiment of the present invention increases, the drug is delivered to the skin of the rat, In the case of the present invention.

That is, referring to FIG. 5, the percutaneous drug delivery patch according to an embodiment of the present invention can release the drug stored in the first chamber by pressing the drug injection button to confirm that the drug is delivered to the skin, It can be seen that when the drug injection button of the transdermal drug delivery patch of the present invention is repetitively pressed with a small force, the number of times of pressing and the area of wetting the skin are linearly related, 1 < / RTI > chamber.

That is, it can be confirmed that the transdermal drug delivery patch of the present invention can release the drug repeatedly stored, and thus the transdermal drug delivery patch of the present invention can be used repeatedly.

In addition, a cellophane tape was attached to the lower end of the first chamber of the percutaneous drug patch according to an embodiment of the present invention to check the drug release amount of the first chamber according to presence or absence of the cellophane tape. FIG. 6 is a graph showing the results of applying the percutaneous drug delivery patch according to an embodiment of the present invention to a skin, a skin with 1-mm cellophane tape attached thereto and a skin without cellophane tape, And the results are shown in Fig.

FIG. 6 is a view for explaining the drug release amount of the percutaneous drug delivery patch according to an embodiment of the present invention. FIG. 6 is a graph showing the drug release amount of the percutaneous drug delivery patch according to an embodiment of the present invention. FIG. 2 is a graph showing the amount of drug released from unattached skin. FIG.

Referring to FIG. 6, it can be seen that the drug release amount shows similar results under the skin in which the glass and cellophane tape exist. That is, it can be seen that the drug release amount is almost similar to that of glass in the skin where 1 mm thick cellophane tape is present. On the other hand, it can be seen that the skin without cellophane tape increases the amount of drug released from the skin where the glass and cellophane tape exist. This means that the cellophane tape suppresses the deformation of the skin or patch at the skin contact surface where the skin contacts with the transdermal drug delivery patch according to an embodiment of the present invention.

Therefore, it can be confirmed that a desired drug can be released more finely and accurately by placing a hard film such as a cellophane tape in the transdermal drug delivery patch of the present invention.

Therefore, it can be confirmed that the drug contained in the first chamber can be supplied to the skin in a desired amount by pressing the drug injection button with a desired number of times or intensity by using the transdermal drug delivery patch of the present invention, By quantifying the dose of the drug to the skin according to the drug release amount and the drug release amount depending on the force for pressing the drug injection button of the transdermal drug delivery patch of the invention, the transdermal drug of the present invention comprising the transdermal drug delivery patch of the present invention It can be seen that the delivery system can monitor and control the amount of drug penetrating into the skin.

It will be apparent to those skilled in the art that various modifications and variations can be made in the present invention without departing from the spirit or scope of the present invention as defined by the following claims. It can be understood that it is possible.

101, 102, 103, 104: transdermal drug delivery patch
110: first chamber
112: Drug injection button
114:
116: Pressure sensor
120: Second chamber
122: Micro needle array
124: Micro Needle Button
126: Cover film
130: fluid channel

Claims (11)

A first chamber containing a drug injection button disposed at an upper end and storing the drug;
A microneedle array having microneedles arrayed on one side facing the skin and facing the skin on the other side facing the skin, and a microneedle button for contacting the microneedle array with the skin, A second chamber for providing the drug to the patient; And
And a fluid channel connecting the first chamber and the second chamber to provide a drug from the first chamber to the second chamber,
When the microneedle array touches the skin and the pressure applied to the microneedle button of the second chamber is removed when the microneedle button of the second chamber is pressed, the microneedle array is removed from the skin, The micro needle holes are formed in the skin by the microneedle arrays, and the microneedle holes are formed in the skin by the microneedle arrays,
Characterized in that when the medicament is provided in the second chamber, the medicament is delivered into the body through the microneedle holes formed by the microneedle array.
Transdermal drug delivery patch.
The method according to claim 1,
Characterized in that the second chamber further comprises a cover film which covers one open side in contact with the skin and in which the microneedle array can penetrate when the microneedle button is pressed.
Transdermal drug delivery patch.
3. The method of claim 2,
Wherein the cover film is a film having at least any one of a material and a thickness of the micro-
Transdermal drug delivery patch.
3. The method of claim 2,
Wherein the cover film is a film having a plurality of openings formed therein so that the array of the micro-
Transdermal drug delivery patch.
The method according to claim 1,
Characterized in that the first chamber is completely filled with the drug.
Transdermal drug delivery patch.
6. The method of claim 5,
Characterized in that the first chamber is a deformable body deformable by an external force.
Transdermal drug delivery patch.
The method according to claim 6,
Wherein the rigid film having rigidity is disposed on the skin contact surface in contact with the skin or the skin contact surface is formed of a rigid material.
Transdermal drug delivery patch.
8. The method of claim 7,
When the drug injection button is pushed, the drug stored in the first chamber is supplied to the second chamber through the fluid channel, and the first chamber is reduced in volume by the volume of the drug supplied to the second chamber Features,
Transdermal drug delivery patch.
8. The method of claim 7,
Wherein the first chamber is formed of a material having elasticity,
When the first chamber is formed of a material having elasticity, the drug injection button includes a micro-penetration portion passing through the drug injection button toward the first chamber,
Wherein the micro-penetration portion is opened when an external force acts on the drug injection button, and is closed when no external force acts on the drug injection button.
Transdermal drug delivery patch.
The method according to claim 1,
Characterized in that the transdermal drug delivery patch comprises a pressure measurement sensor capable of measuring the pressure of the drug injection button.
Transdermal drug delivery patch.
The method according to claim 1,
Characterized in that the fluid channel is a microfluidic channel having a micro-sized diameter and capable of fluid movement.
Transdermal drug delivery patch.

Images